News > US trial of AstraZeneca COVID-19 vaccine shows 74% efficacy, 83.5% in those above 65

US trial of AstraZeneca COVID-19 vaccine shows 74% efficacy, 83.5% in those above 65

National Herald | 30/09/2021 06:41 PM | Click to read full article

AstraZeneca or the Oxford vaccine was safe and had 74% efficacy at preventing symptomatic SARS-CoV-2, and it increased to 83.5% in people aged 65 across diverse populations that included older adults in the US, Chile, and Peru, stated the results of the company’s clinical trial published in The New England Journal of Medicine on September 29.

The paper stated that high vaccine efficacy was consistent across a range of demographic subgroups.